Trial Profile
Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Itacitinib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 17 Nov 2022 Status changed from active, no longer recruiting to discontinued.
- 01 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2021 Planned End Date changed from 30 Sep 2023 to 31 Jan 2025.